SEARCH

SEARCH BY CITATION

References

  • 1
    Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 2004; 126: 16201633.
  • 2
    Rioux KP, Madsen KL, Fedorak RN. The role of enteric microflora in inflammatory bowel disease: human and animal studies with probiotics and prebiotics. Gastroenterol Clin N Am 34 2005: 465482.
  • 3
    Vinderola G, Matar C, Perdigón G. Role of intestinal epithelial cells in immune effects mediated by gram-positive probiotic bacteria: involvement of Toll-like receptors. Clin Diagn Lab Immunol 2005; 12: 10751084.
  • 4
    Rachmilewitz D, Katakura K, Karmeli F, Hayashi T, Reinus C, Rudensky B, et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 2004; 126: 520528.
  • 5
    Fedorak RN, Madsen KL. Probiotics and the management of inflammatory bowel disease. Inflamm Bowel Dis 2004; 10: 286299.
  • 6
    Jijon H, Backer J, Diaz H, Yeung H, Thiel D, McKaigney C, et al. DNA from probiotic bacteria modulates murine and human epithelial and immune function. Gastroenterology 2004; 126: 13581373.
  • 7
    Madsen KL, Doyle JS, Jewell LK, Tavernini MM, Fedorak RN. Lactobacillus species prevents colitis in interleukin-10 gene-deficient mice. Gastroenterology 1999; 116: 11071114.
  • 8
    Schultz M, Veltkamp C, Dieleman LA, Grenther WB, Wyrick PB, Tonkonogy SL, Sartor RB. Lactobacillus plantarum 299V in the treatment and prevention of spontaneous colitis in IL-10 deficient mice. Inflamm Bowel Dis 2002; 8: 7180.
  • 9
    Madsen K, Cornish A, Soper P, McKaigney C, Jijon H, Yachimec C, et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001; 121: 580591.
  • 10
    Montalto M, Maggiano N, Ricci R, Curigliano V, Santoro L, Di Nicuolo F, et al. Lactobacillus acidophilus protects tight junctions from aspirin damage in HT-29 cells. Digestion 2004; 69: 225228.
  • 11
    Mack DR, Ahrne S, Hyde L, Wei S, Hollingsworth MA. Extracellular MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells in vitro. Gut 2003; 52: 827833.
  • 12
    Freitas M, Tavan E, Cayuela C, Diop L, Sapin C, Truenan G. Host pathogens cross-talk. Indigenous bacteria and probiotics also play the game. Biol Cell 2003; 95: 503506.
  • 13
    Resta-Lenert S, Barrett KE. Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli. Gut 2003; 52: 988997.
  • 14
    Zhang S, Wang W, Ren W, Dai Q, He B, Zhou K. Effects of lactulose on intestinal endotoxin and bacterial translocation in cirrhotic rats. Chin Med J 2003; 116: 767771.
  • 15
    Perez-Paramo M, Munoz J, Albillos A, Freile I, Portero F, Santos M, et al. Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites. HEPATOLOGY 2000; 31: 4348.
  • 16
    Pascual S, Such J, Esteban A, Zapater P, Casellas JA, Aparicio JR, et al. Intestinal permeability is increased in patients with advanced cirrhosis. Hepatogastroenterology 2003; 50: 14821486.
  • 17
    Fujii T, Seki T, Maruoka M, Tanaka J, Kawashima Y, Watanabe T, et al. Lactulose-L-rhamnose intestinal permeability test in patients with liver cirrhosis. Hepatol Res 2001; 19: 158169.
  • 18
    Campillo B, Pernet P, Bories PN, Richardet JP, Devanlay M, Aussel C. Intestinal permeability in liver cirrhosis: relationship with severe septic complications. Eur J Gastroenterol Hepatol 1999; 11: 755759.
  • 19
    Guarner C, Soriano G. Bacterial translocation and its consequences in patients with cirrhosis. Eur J Gastroenterol Hepatol 2005; 17: 2731.
  • 20
    Liu Q, Duan ZP, Ha DK, Bengmark S, Kurtovic J, Riordan SM. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. HEPATOLOGY 2004; 39: 14411449.
  • 21
    Loguercio C, Abbiati R, Rinaldi M, Romano A, Del Vecchio BC, Coltorti M. Long-term effects of Enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1-2 hepatic encephalopathy. J Hepatol 1995; 23: 3946.
  • 22
    Loguercio C, Del Vecchio BC, Coltorti M. Enterococcus lactic acid bacteria strain SF68 and lactulose in hepatic encephalopathy: a controlled study. J Int Med Res 1987; 15: 335343.
  • 23
    Read AE, McCarthy CF, Heaton KW, Laidlaw J. Lactobacillus acidophilus (enpac) in treatment of hepatic encephalopathy. Br Med J 1966; 5498: 12671269.
  • 24
    MacBeth WA, Kass EH, McDermott WV. Treatment of hepatic encephalopathy by alteration of the intestinal flora with lactobacillus acidophilus. Lancet 1965; 191: 399403.
  • 25
    Loguercio C, Federico A, Tuccillo C, Terracciano F, D'Auria MV, De Simone C, et al. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol 2005; 39: 540543.
  • 26
    Madsen KL, Yanchar NL, Sigalet DL, Reigel T, Fedorak RN. FK506 increases permeability in rat intestine by inhibiting mitochondrial function. Gastroenterology 1995; 109: 107114.
  • 27
    Gabe SM, Bjarnason I, Tolou-Ghamari Z, Tredger JM, Johnson PG, Barclay GR, et al. The effect of tacrolimus (FK506) on intestinal barrier function and cellular energy production in humans. Gastroenterology 1998; 115: 6774.
  • 28
    Parrilli G, Abazia C, Sarnelli G, Corsaro MM, Coccoli P, Viglione L, et al. Effect of chronic administration of tacrolimus and cyclosporine on human gastrointestinal permeability. Liver Transpl 2003; 9: 484488.
  • 29
    Rayes N, Seehofer D, Theruvath T, Schiller RA, Langrehr JM, Jonas S, et al. Supply of pre- and probiotics reduces bacterial infection rates after liver transplantation—a randomized, double blind trial. Am J Transplant 2005; 5: 125130.
  • 30
    Rayes N, Seehofer D, Hansen S, Boucsein K, Muller AR, Serke S, et al. Early enteral supply of lactobacillus and fiber versus selective bowel decontamination: a controlled trial in liver transplant recipients. Transplantation 2002; 74: 123127.
  • 31
    Yasui H, Nagoake N, Mike A. Detection of Bifidobacterium strains that induce large quantities of IgA. Microb Ecol Health Dis 1992; 5: 155.
  • 32
    Garcia-Lafuente A, Antolin M, Guarner F, Crespo E, Malagelada JR. Modulation of colonic barrier function by the composition of the commensal flora in the rat. Gut 2001; 48: 503507.
  • 33
    McNaught CE, Woodcock NP, Anderson AD, MacFie J. A prospective randomized trial of probiotics in critically ill patients. Clin Nutr 2005; 24: 211219.
  • 34
    Munoz P, Bouza E, Cuenca-Estrella M, Eiros JM, Perez MJ, Sanchez-Somolinos M, et al. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis 2005; 40: 16251634.
  • 35
    Land MH, Rouster-Stevens K, Woods CR, Cannon ML, Cnota J, Shetty AK. Lactobacillus sepsis associated with probiotic therapy. Pediatrics 2005; 115: 178181.
  • 36
    Herbrecht R, Nivoix Y. Saccharomyces cerevisiae fungemia: an adverse effect of Saccharomyces boulardii probiotic administration. Clin Infect Dis 2005; 40: 16351637.
  • 37
    Henriksson A, Borody T, Clancy R. Probiotics under the regulatory microscope. Expert Opin Drug Saf 2005; 4: 11351143.